Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Live Updates Live Coverage Updates appear automatically as they are published. MassterCard Charges Ahead 10:00 am In further ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and Rinvoq. S&P Global said second-quarter profit rose due to "resilience in the ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

Gildan Activewear more than doubled its second-quarter profit. However, the Canada apparel manufacturer narrowed its adjusted earnings view but backed its full-year revenue guidance expectations.

Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust performance in its Growth Portfolio, leading the pharmaceutical giant to ...